PubRank

James L Ellis

Author PubWeight™ 19.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013 3.40
2 SRT1720 improves survival and healthspan of obese mice. Sci Rep 2011 1.81
3 Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J Med Chem 2004 1.33
4 SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS One 2012 1.23
5 Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008 1.11
6 Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol 2003 1.01
7 SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 2010 1.00
8 Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1. Proc Natl Acad Sci U S A 2013 1.00
9 SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 2014 0.94
10 Carboxamide SIRT1 inhibitors block DBC1 binding via an acetylation-independent mechanism. Cell Cycle 2013 0.83
11 Effect of olvanil on the afferent and efferent function of capsaicin-sensitive C-fibers in guinea pig airways. Eur J Pharmacol 2003 0.80
12 Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem 2007 0.79
13 PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. Shock 2016 0.78
14 Sirt1 Activation Markedly Alters Transcription Profiles and Improves Outcome in Experimental Sepsis. Shock 2015 0.77
15 The study of airway primary afferent neuron excitability. Curr Opin Pharmacol 2002 0.76
16 A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochem Pharmacol 2005 0.76
17 Synthesis and anti-inflammatory activity of a series of N-substituted naproxen glycolamides: nitric oxide-donor naproxen prodrugs. Bioorg Med Chem 2005 0.76
18 5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. Bioorg Med Chem Lett 2004 0.75
19 Modulation of citric acid-induced cough following lipopolysaccharide-mediated neutrophilia in the guinea pig. Pulm Pharmacol Ther 2006 0.75
20 UCB 62045: pharmacology of a novel, dual-function anti-inflammatory agent with histamine type 1 receptor antagonist and 5-lipoxygenase inhibitor activity. Chest 2003 0.75
21 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett 2004 0.75
22 Rat model for evaluation of therapeutics on peripheral vascular resistance. Curr Protoc Pharmacol 2006 0.75